Marc Engelhardt
Allschwil, BL, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications
Plasma and intrapulmonary pharmacokinetics of ceftibuten and ledaborbactam in healthy male and female adults.
Journal: Antimicrobial agents and chemotherapy
Published: April 20, 2026
A plain language summary of the safety and effectiveness of isavuconazole for the treatment of serious fungal disease in children with a weakened immune system.
Journal: Expert review of anti-infective therapy
Published: July 11, 2025
Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance.
Journal: PloS one
Published: February 25, 2025
Safety, outcomes, and pharmacokinetics of isavuconazole as a treatment for invasive fungal diseases in pediatric patients: a non-comparative phase 2 trial.
Journal: Antimicrobial agents and chemotherapy
Published: November 14, 2024
Impact of obesity on clinical outcomes in patients treated with ceftobiprole: results from Phase 3 clinical trials.
Journal: The Journal of antimicrobial chemotherapy
Published: November 05, 2024
Lisavanbulin (BAL101553), a novel microtubule inhibitor, plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma.
Journal: Neuro-oncology advances
Published: October 07, 2024
A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma.
Journal: Cell reports. Medicine
Published: June 29, 2024
Ceftobiprole for Staphylococcus aureus Bacteremia. Reply.
Journal: The New England journal of medicine
Published: December 29, 2023
Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.
Journal: JNCI cancer spectrum
Published: November 27, 2023
Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia.
Journal: The New England journal of medicine
Published: September 27, 2023
The microtubule-targeted agent lisavanbulin (BAL101553) shows anti-tumor activity in lymphoma models.
Journal: American journal of cancer research
Published: February 01, 2023
Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.
Journal: Investigational new drugs
Published: December 23, 2022
Last Updated: 09/26/2026